|
|
 |
|
 |
Antibody Production and Purification Unit
A NEW CCR CORE FACILITY: CCR is establishing a new Core Facility, the Antibody Production and Purification Unit, within the Office of Science and Technology Partnerships. The Antibody and Protein Purification Unit (APPU) has been established for the design and production of peptide specific antibodies to proteins of interest to the Principle Investigators (PI’s) at the CCR. After consultation with the PI’s, APPU staff determines peptide sequences to be used as antigens for antibody production, conjugates the peptides to carrier proteins for immunization, affinity purifies the resulting antibodies, and evaluates their specificity by western blot analysis. APPU has great experience in formatting diagnostic assays using enzymatic or fluorescent labels that it can conjugate to these antibodies. When applicable, APPU can help PI’s with the development of immunoassays to their proteins. APPU has extensive experience in the characterization of proteins for post-translational modifications and binding partners. APPU can assist PI’S with the isolation of their proteins of interest using the affinity-purified antibodies as markers in western blots. The isolated proteins are then available as standards for diagnostic assays, as affinity reagents for binding partner studies, or for studies of post-translational modifications. It can help with the design of experiments for determining structure and function of the proteins. We are particularly interested in developing methods for the determination of binding interfaces in protein-protein interactions. APPU has experience in the development of novel affinity reagents and is capable of rigorously evaluating new technologies. They are in the process of helping with the CCR initiatives related to the creation of new tools for discovery and characterization of novel molecular targets. The laboratory in the process of overseeing collaborations with commercial companies interested in providing reagents for use by NCI researchers. Contact information: Paul Goldsmith, Ph.D. |
A service of the National Cancer Institute
